Yunu is revolutionizing the imaging ecosystem in clinical trials

Yunu, an innovative company based in Cary, North Carolina, stands out for its innovative approach in the field of clinical trials. Founded by Jeff Sorenson and Gael Kuhn, Yunu aims to effectively integrate medical imaging into research, thus remedying a disorganized and inefficient workflow. Historically, this sector has experienced delays and lacked precision, negatively impacting the development of innovative therapies, especially in oncology, as well as in the cardiac, neurological, and pulmonary fields.

Thanks to the expertise in medical imaging and artificial intelligence of the co-founders, Yunu has launched a promising solution after identifying and understanding the challenges related to imaging in clinical trials. The company obtained the license for a technology developed by Dr. Gordon Harris, who became a co-founder and Chief Science Officer, optimizing the imaging workflow.

Just a year and a half after its launch, Yunu is involved in over 4,200 active clinical trials and collaborates with more than 25% of the cancer centers designated by the National Cancer Institute in the United States. The company has also become the partner of choice for several major entities and pharmaceutical sponsors, marking a significant advancement towards improving efficiency, precision, and interoperability in imaging for clinical trials.

This success could well transform the future of patient care and revolutionize the development of new therapies, making cutting-edge treatments accessible to a wider audience. Yunu continues to expand its influence in the landscape of clinical trials, optimizing the use of imaging data for faster and more informed decision-making in therapy development.